Skip to main content
Erschienen in: Journal of Neurology 12/2017

14.10.2017 | Original Communication

The natural history of depressive symptoms in patients with incident Parkinson’s disease: a prospective cohort study

verfasst von: Jan Petter Larsen, Ingvild Dalen, Kenn Freddy Pedersen, Ole-Bjørn Tysnes

Erschienen in: Journal of Neurology | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Abstract

Depression is common in patients with Parkinson disease and causes suffering and increased caregiver burden. A better understanding of depressive symptoms in Parkinson disease, their progression, and risk factors may, therefore, benefit management of these patients. The present study included 187 drug-naïve patients with incident PD and 166 controls from the population-based Norwegian ParkWest project. Depressive symptoms were examined with the Montgomery and Aasberg Depression Rating Scale (MADRS) at time of diagnosis and inclusion in the study and after 1, 3, 5, and 7 years of follow-up. Associations between MADRS scores and risk factors were assessed using generalized estimating equations (GEE). The mean MADRS score from all 823 examinations during the study period was 4.2 in patients and 1.3 in 732 examinations among controls. Among controls, the occurrence of depressive symptoms was also lower and rather stable during follow-up, while in patients, we observed a decrease from time of diagnosis and until the 1-year visit, followed by a steady increase in these symptoms over time. Factors associated with higher MADRS score in the multivariable model were female sex, being dependent, higher pain score, higher Unified PD Rating Scale (UPDRS) motor score, and lower Mini-Mental State Examination (MMSE) score. The results from this study underscore the importance and frequency of depressive symptoms in patients with early PD. Furthermore, risk factors that may be considered PD-nonspecific are associated with depressive symptoms as are factors that reflect the progression of PD.
Literatur
1.
Zurück zum Zitat Blazer DG (2003) Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 58:249–265CrossRefPubMed Blazer DG (2003) Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 58:249–265CrossRefPubMed
2.
Zurück zum Zitat Cole M, Dendukuri N (2003) Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 160:1147–1156CrossRefPubMed Cole M, Dendukuri N (2003) Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 160:1147–1156CrossRefPubMed
3.
Zurück zum Zitat Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRefPubMed Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189CrossRefPubMed
5.
Zurück zum Zitat Vu TC, Nutt JG, Holford NH (2012) Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. Br J Clin Pharmacol 74:267–283CrossRefPubMedPubMedCentral Vu TC, Nutt JG, Holford NH (2012) Progression of motor and nonmotor features of Parkinson’s disease and their response to treatment. Br J Clin Pharmacol 74:267–283CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Bega D, Luo S, Fernandez H et al (2015) Impact of depression on progression of impairment and disability in early Parkinson’s disease. Mov Disord Clin Pract 2:371–378CrossRefPubMedPubMedCentral Bega D, Luo S, Fernandez H et al (2015) Impact of depression on progression of impairment and disability in early Parkinson’s disease. Mov Disord Clin Pract 2:371–378CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P (2011) Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47CrossRefPubMed Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P (2011) Depression in Parkinson disease—epidemiology, mechanisms and management. Nat Rev Neurol 8:35–47CrossRefPubMed
8.
Zurück zum Zitat Suzuki A, Aoshima T, Fukasawa T et al (2005) A three-factor model of the MADRS in major depressive disorder. Depress Anxiety 21:95–97CrossRefPubMed Suzuki A, Aoshima T, Fukasawa T et al (2005) A three-factor model of the MADRS in major depressive disorder. Depress Anxiety 21:95–97CrossRefPubMed
9.
Zurück zum Zitat Leentjens AF, Moonen AJ, Dujardin K et al (2013) Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology 81:1036–1043CrossRefPubMedPubMedCentral Leentjens AF, Moonen AJ, Dujardin K et al (2013) Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology 81:1036–1043CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Alves G, Muller B, Herlofson K et al (2009) Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 80:851–857CrossRefPubMed Alves G, Muller B, Herlofson K et al (2009) Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 80:851–857CrossRefPubMed
11.
Zurück zum Zitat Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42:1142–1146CrossRefPubMed Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ (1992) What features improve the accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 42:1142–1146CrossRefPubMed
12.
Zurück zum Zitat Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRefPubMed Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39CrossRefPubMed
13.
Zurück zum Zitat Fahn S, Elton RL, Development Committee UPDRS (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease. Macmillan, Florham Park, pp 153–163 Fahn S, Elton RL, Development Committee UPDRS (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease. Macmillan, Florham Park, pp 153–163
14.
Zurück zum Zitat Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534CrossRefPubMed Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534CrossRefPubMed
15.
Zurück zum Zitat Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMed
16.
Zurück zum Zitat Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653CrossRefPubMed
17.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
18.
Zurück zum Zitat de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56:221–229CrossRefPubMed de Groot V, Beckerman H, Lankhorst GJ, Bouter LM (2003) How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56:221–229CrossRefPubMed
19.
Zurück zum Zitat Schwab JF, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson’s disease. E & S Livingston, Edinburgh, pp 152–157 Schwab JF, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson IML (eds) Third symposium on Parkinson’s disease. E & S Livingston, Edinburgh, pp 152–157
20.
Zurück zum Zitat Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefPubMed Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefPubMed
21.
Zurück zum Zitat Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMedPubMedCentral Schrag A, Barone P, Brown RG et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord 22:1077–1092CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Snaith RP, Harrop FM, Newby PA, Teale C (1986) Grade scores of the Montgomery-Asberg depression and the clinical anxiety scales. Br J Psychiatry 148:599–601CrossRefPubMed Snaith RP, Harrop FM, Newby PA, Teale C (1986) Grade scores of the Montgomery-Asberg depression and the clinical anxiety scales. Br J Psychiatry 148:599–601CrossRefPubMed
23.
Zurück zum Zitat Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW (2000) The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry 15:644–649CrossRefPubMed Leentjens AF, Verhey FR, Lousberg R, Spitsbergen H, Wilmink FW (2000) The validity of the Hamilton and Montgomery-Asberg depression rating scales as screening and diagnostic tools for depression in Parkinson’s disease. Int J Geriatr Psychiatry 15:644–649CrossRefPubMed
24.
Zurück zum Zitat Cummings JL, Mega M, Gray K et al (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314CrossRefPubMed Cummings JL, Mega M, Gray K et al (1994) The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314CrossRefPubMed
25.
Zurück zum Zitat Kurland BF, Heagerty PJ (2005) Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. Biostatistics 6:241–258CrossRefPubMed Kurland BF, Heagerty PJ (2005) Directly parameterized regression conditioning on being alive: analysis of longitudinal data truncated by deaths. Biostatistics 6:241–258CrossRefPubMed
27.
Zurück zum Zitat Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580CrossRefPubMed
28.
Zurück zum Zitat Xu YY, Kuo SH, Liang Z et al (2015) The natural history of depression in Parkinson’s disease within 30-month follow-up. Parkinsons Dis 2015:362892PubMedPubMedCentral Xu YY, Kuo SH, Liang Z et al (2015) The natural history of depression in Parkinson’s disease within 30-month follow-up. Parkinsons Dis 2015:362892PubMedPubMedCentral
29.
Zurück zum Zitat Marsh L, McDonald WM, Cummings J, Ravina B (2006) Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158CrossRefPubMed Marsh L, McDonald WM, Cummings J, Ravina B (2006) Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158CrossRefPubMed
30.
Zurück zum Zitat Stek ML, Vinkers DJ, Gussekloo J, van der Mast RC, Beekman AT, Westendorp RG (2006) Natural history of depression in the oldest old: population-based prospective study. Br J Psychiatry 188:65–69CrossRefPubMed Stek ML, Vinkers DJ, Gussekloo J, van der Mast RC, Beekman AT, Westendorp RG (2006) Natural history of depression in the oldest old: population-based prospective study. Br J Psychiatry 188:65–69CrossRefPubMed
31.
Zurück zum Zitat Leentjens AF, Moonen AJ, Dujardin K et al (2013) Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology 81:1036–1043CrossRefPubMedPubMedCentral Leentjens AF, Moonen AJ, Dujardin K et al (2013) Modeling depression in Parkinson disease: disease-specific and nonspecific risk factors. Neurology 81:1036–1043CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Chen JJ, Marsh L (2013) Depression in Parkinson’s disease: identification and management. Pharmacotherapy 33:972–983CrossRefPubMed Chen JJ, Marsh L (2013) Depression in Parkinson’s disease: identification and management. Pharmacotherapy 33:972–983CrossRefPubMed
Metadaten
Titel
The natural history of depressive symptoms in patients with incident Parkinson’s disease: a prospective cohort study
verfasst von
Jan Petter Larsen
Ingvild Dalen
Kenn Freddy Pedersen
Ole-Bjørn Tysnes
Publikationsdatum
14.10.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 12/2017
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-017-8638-1

Weitere Artikel der Ausgabe 12/2017

Journal of Neurology 12/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.